Other cardiomyopathies

Article written and reviewed by Dr Luca Moretti

The category of other cardiomyopathies encompasses conditions that cannot be adequately understood through a single ventricular shape. Some represent an anatomic trait that acquires significance only in the presence of dysfunction, fibrosis or familial occurrence; others are myocardial responses to hormones, deficiencies, organ failure or catecholamine stress. The common denominator is therefore not a shared pathogenesis, but the need to move from phenotype to cause before assigning prognosis and treatment.

This group is vulnerable to two opposite errors. The first is calling any imaging peculiarity a cardiomyopathy, turning a common variant into a disease; the second is attributing every abnormality to the known systemic condition and overlooking a concomitant genetic cardiomyopathy. Proper assessment separates description, syndrome and etiologic diagnosis, reconstructing timing, hemodynamic load, tissue characteristics and family history. The diagnostic hierarchy prevents a general label from replacing clinical reasoning.

Left ventricular hypertrabeculation is first and foremost a morphologic finding, also observable during pregnancy, athletic activity and in structurally normal hearts. Noncompaction cardiomyopathy instead denotes a pathologic context in which trabeculation is associated with dysfunction, arrhythmias, thromboembolism, genetic disease or familial involvement. The distinction is not merely lexical: it prevents transferring the risk of selected cohorts to healthy people who exceed a sensitive geometric criterion.

Takotsubo syndrome is an acute, often transient ventricular failure related to an interaction among the nervous system, catecholamines, the microcirculation and myocardial susceptibility. Endocrine cardiomyopathy instead includes remodeling produced by thyroid hormones, catecholamines, growth hormone, cortisol and other hormonal abnormalities. In both, the heart responds to extracardiac signals, but timing, distribution of dysfunction and causal strategies are profoundly different.

Nutritional cardiomyopathy results from deficiencies or imbalances that compromise energy production, antioxidant defenses or cellular structure. Cirrhotic cardiomyopathy arises in the hyperdynamic circulation and complex signaling of cirrhosis, whereas uremic cardiomyopathy combines hypertrophy, fibrosis and dysfunction in the setting of chronic kidney disease. The host disease is not background: it determines loading conditions, medications, interventions and myocardial reversibility.

Nosologic boundaries and clinical language

A cardiomyopathy is a disease of the heart muscle in which the phenotype is not explained solely by coronary artery disease, hypertension, valvular disease or congenital heart disease sufficient to produce it. This operational definition does not exclude systemic influences, because many causes act through metabolism, immunity, hormones or organ failure. It does, however, require demonstration that myocardial involvement has its own coherence and clinical consequences. The causal link must be stronger than simple coexistence.

Descriptive terms retain value when they do not claim to anticipate etiology. Hypertrabeculation, hypertrophy, dilation, edema and fibrosis state what the examination shows; by themselves they do not establish whether the process is adaptive, inherited or acquired. Defining the phenotype first makes it possible to compare longitudinal data and select targeted tests. Neutral description is particularly important when historical criteria were derived from small groups of very ill patients.

The term secondary may misleadingly suggest that the heart disease is marginal or always disappears when the cause is corrected. In cirrhosis, kidney disease and endocrinopathies, injury can become autonomous because of fibrosis, capillary rarefaction and irreversible remodeling. In Takotsubo, by contrast, recovery of ejection fraction does not erase the risk of the acute phase or every residual functional abnormality. Biologic reversibility is a continuum to be measured, not a property assigned by category.

The same person may have multiple determinants. A patient with kidney failure may have a sarcomeric variant; a woman with coronary artery disease may develop Takotsubo; alcoholic cirrhosis may be associated with direct toxicity and thiamine deficiency. The diagnostic method must therefore quantify competing contributions rather than impose a single explanation. Multiple causality is common in acquired phenotypes and modifies the proportion of recoverable injury.

Trabecular architecture: trait, adaptation or disease

Trabeculae are normal components of the endocardial surface, and their visibility depends on technique, imaging plane, resolution, cavity volume and contouring method. Ratios of trabeculated to compacted layer or percentages of trabeculated mass turn a continuous geometry into a threshold. These measurements improve descriptive reproducibility, but do not create a clear biological separation. The value of the criterion depends on the population in which it is applied.

Athletes, pregnant women and people without heart disease may meet proposed criteria for noncompaction, especially when ventricular volume or endocardial definition increases. In many cases function remains normal and trabeculation does not predict events independently of other findings. Race, body surface area and hemodynamic load can modify the apparent prevalence. The physiologic context protects against overdiagnosis and unjustified restrictions.

Pathologic suspicion increases when reduced function, unexplained dilation, LGE, arrhythmias, emboli, congenital heart disease, neuromuscular disease or familial segregation coexist. In this setting, morphology may be a marker of an underlying cardiomyopathy, often involving genes shared with dilated or hypertrophic forms. There is, however, no single specific gene that turns every trabecular pattern into an autonomous entity. Phenotypic concordance carries more weight than isolated crossing of a threshold.

In neonates and children, greater caution is required because the association with genetic syndromes, metabolic defects and neuromuscular diseases is more relevant and the heart may evolve rapidly. In an asymptomatic adult with normal function, normal ECG and no family history, an incidental finding instead requires proportionality. Age and pretest probability change the meaning of the same image. Longitudinal interpretation replaces an instantaneous diagnosis based on morphology alone.

Acute stress-mediated dysfunction

Takotsubo presents as an acute coronary syndrome with pain, dyspnea, ECG abnormalities and elevated biomarkers, but regional dysfunction often extends beyond the territory of a single coronary artery. An emotional trigger is not obligatory, and physical, neurologic or critical illness-related stressors are common, especially in men and hospitalized patients. Concomitant coronary artery disease does not exclude the diagnosis. Ischemic mimicry therefore requires initial management as an emergency and demonstration of appropriate coronary anatomy.

Catecholamine excess, the central sympathetic response, microvascular dysfunction and direct toxicity contribute in varying proportions. Apical, midventricular, basal or focal patterns show that this is not merely a geometric form. Pheochromocytoma and neurologic disorders can trigger indistinguishable presentations, requiring a context-guided search for the cause. The heart-brain network explains the syndrome better than the reductive broken-heart formulation.

The acute phase may include pulmonary edema, shock, dynamic left ventricular outflow tract obstruction, mitral regurgitation, arrhythmias, QT prolongation and apical thrombus. The choice of inotropes, vasodilators and mechanical support depends on physiology and cannot be uniform, especially when obstruction is present. Ejection fraction tends to recover, but recurrence and mortality are not zero. Immediate risk should not be minimized because of expected transience.

Magnetic resonance helps distinguish edema, infarction and myocarditis, while follow-up documents recovery of wall motion. Chronic therapies often used after the event do not all have specific randomized evidence, and any benefit should be distinguished from treatment of concomitant hypertension, arrhythmias or coronary artery disease. Stress management does not imply that the disease is imaginary or voluntary. Integrated rehabilitation addresses cardiac, neurologic and psychological components without assigning blame.

Endocrine signals and myocardial remodeling

Hormones modify heart rate, contractility, vascular resistance, volume, metabolism and cell growth. Hyperthyroidism and thyrotoxicosis promote tachycardia, atrial fibrillation, high-output states and sometimes dilated dysfunction; hypothyroidism reduces chronotropy and relaxation, increases resistance and may be associated with effusion. Correcting thyroid dysfunction is essential, but concomitant ischemic or valvular heart disease should be treated independently. The hemodynamic signature guides interpretation without replacing hormone measurements.

Acromegaly and chronic excess of growth hormone and IGF-1 can produce biventricular hypertrophy, diastolic dysfunction, arrhythmias and valvular disease, aggravated by hypertension, diabetes and sleep apnea. Hypercortisolism instead acts through blood pressure, adiposity, metabolism and thrombotic risk more than through a single specific pattern. In diabetes, lipotoxicity, microvascular dysfunction and altered energetics contribute to dysfunction, but separating diabetic cardiomyopathy from common comorbidities requires rigor. Phenotypic specificity therefore varies among endocrinopathies.

Pheochromocytoma and paraganglioma can cause hypertensive crises, catecholamine myocarditis, a dilated form or a Takotsubo pattern. Recognizing the tumor radically changes pharmacologic preparation and definitive treatment, whereas cardiac biopsy is not the first tool in a suggestive endocrine presentation. Headache, sweating, palpitations and labile blood pressure are clues, not sufficient criteria. The catecholaminergic cause must be documented with appropriate biochemical testing and imaging.

Response to hormonal normalization depends on duration, fibrosis and comorbidities. Function and heart rate can improve rapidly, whereas mass and tissue changes require months or remain abnormal. Follow-up should therefore measure both endocrine control and cardiac remodeling with distinct endpoints. Dual remission, biochemical and cardiac, is not automatically simultaneous.

Deficiencies, malabsorption and energetic vulnerability

The heart depends on micronutrients that support oxidative decarboxylation, the respiratory chain, antioxidant defenses and fatty acid metabolism. A deficiency becomes clinically relevant when stores, absorption and requirements become sufficiently imbalanced to limit function. Thiamine, selenium and carnitine are well-known examples, but actual risk depends on diet, alcohol, diuretics, dialysis, artificial nutrition, bariatric surgery and malabsorption. Nutritional history should precede indiscriminate empirical supplementation.

Thiamine deficiency can cause vasodilation, high-output circulation, sodium and water retention and, in advanced cases, collapse, whereas other deficiencies directly impair bioenergetics or oxidative stability. Biomarkers are not always immediately available or perfectly correlated with tissue status. In unstable high-risk patients, prompt treatment may precede confirmation without foregoing specimen collection and a search for alternative causes. Low-risk therapy does not, however, turn a nonspecific response into absolute etiologic proof.

Refeeding can precipitate hypophosphatemia, hypokalemia, hypomagnesemia, sodium retention and heart failure in a severely malnourished person. The danger arises not only from the initial deficiency but from the speed at which metabolism is reactivated. Electrolyte correction, thiamine and controlled caloric advancement are part of cardiologic prevention. The metabolic transition is an active clinical phase, not simply a return to a normal diet.

A carnitine transporter mutation or another inherited metabolic disease should not be confused with an acquired dietary deficiency, even though treatment may share a substrate. Age, family history, hypoglycemia, rhabdomyolysis and the acylcarnitine profile guide evaluation. Biochemical precision distinguishes nutritional replacement from permanent therapy for a genetic disease.

Cirrhosis and hidden cardiac reserve

Cirrhosis produces splanchnic vasodilation, neurohormonal activation, plasma volume expansion and a hyperdynamic circulation. At rest, cardiac output may be high and mask an inadequate contractile response; infection, hemorrhage, TIPS, surgery or transplantation reveal limited reserve. Diastolic dysfunction, abnormal strain and reduced stress response are relevant components, but should be interpreted relative to age and loading conditions. Apparent normality of ejection fraction is not equivalent to a normal myocardium.

Inflammatory mediators, nitric oxide, endocannabinoids, bile acids, abnormalities of beta-adrenergic receptors and the cardiomyocyte membrane have been implicated in pathophysiology. QT prolongation and chronotropic incompetence may accompany the condition without being specific. Alcohol, hemochromatosis, amyloidosis, coronary artery disease and portal hypertension introduce competing causes that should be excluded. Cirrhotic cardiomyopathy is therefore a positive diagnosis in the appropriate context, not a catch-all for every cardiac disease in a patient with cirrhosis.

Contemporary criteria emphasize ejection fraction, strain and multiple parameters of diastolic function, moving beyond historical thresholds that were highly preload-sensitive. No single index is immune to the volume changes typical of cirrhosis. Pre-TIPS or pre-transplant assessment should integrate symptoms, ECG, biomarkers, echocardiography and, when needed, additional testing. Perioperative risk stratification seeks inability to tolerate stress, not merely resting abnormalities.

After liver transplantation some features may improve, whereas perioperative stress can unmask acute heart failure. Candidate selection and fluid management require collaboration among hepatology, anesthesia and cardiology. Attributing all dysfunction to cirrhosis in advance risks transplanting a patient with unrecognized autonomous heart disease. Post-transplant reversibility should be estimated through a complete differential diagnosis.

Kidney disease, hypertrophy and fibrosis

Cardiomyopathy associated with chronic kidney disease combines pressure and volume overload with anemia, inflammation, oxidative stress, mineral abnormalities, toxins and microvascular dysfunction. Left ventricular hypertrophy is common, but does not exhaust the phenotype: interstitial fibrosis, diastolic dysfunction, reduced reserve and electrical instability contribute to mortality. The cardiorenal network makes an explanation based on blood pressure alone insufficient.

Weight and volume change between dialysis sessions, altering diameters, gradients and Doppler parameters. Echocardiography should report its temporal relationship to dialysis and dry weight; biomarkers such as troponin and natriuretic peptides require comparison with usual values and kidney function. Magnetic resonance with mapping can characterize fibrosis, but contrast administration is evaluated according to glomerular filtration rate and agent type. Temporal standardization makes otherwise discordant measurements interpretable.

High-flow fistula, severe anemia, ischemia, valvular calcification and sleep apnea may dominate the picture and have specific interventions. Even beta-2-microglobulin amyloid deposition, now less common with modern techniques, is not the same as typical uremic remodeling. Diagnosis should decompose the correctable determinants. The uremic phenotype does not justify abandoning the search for treatable causes.

Blood pressure and volume control, cautious correction of anemia, mineral management and heart failure therapy are adapted to glomerular filtration rate, potassium and dialysis. Kidney transplantation can promote regression of hypertrophy and functional improvement, but advanced fibrosis and concomitant heart disease limit recovery. Cardiorenal care measures congestion, function, drug tolerance and vascular access together.

Integrated diagnostic pathway

The history reconstructs when the phenotype appeared relative to pregnancy, exercise, infection, neurologic stress, hormonal change, malnutrition, cirrhosis or kidney failure. The temporal sequence is often more discriminating than the final finding. Medications, alcohol, substances, surgery and replacement treatments are recorded with dose and duration. Causal chronology selects tests and identifies windows of reversibility.

ECG, echocardiography and rhythm monitoring define mechanics and electrophysiology. Magnetic resonance is used when it must distinguish scar, edema, infiltration, ischemia or an unclear phenotype, while coronary angiography or CT responds to the probability of coronary artery disease. Laboratory tests are targeted to thyroid function, plasma or urinary metanephrines, pituitary axis, micronutrients, liver and kidney according to context. Diagnostic sequencing avoids broad panels without a clinical question.

Genetic testing gains value in the presence of unexplained dysfunction, family history, congenital heart disease, neuromuscular signs or a recognizable cardiomyopathic phenotype. A variant of uncertain significance does not confirm that trabeculation is pathologic and should not automatically extend surveillance or restrictions to relatives. Conversely, a negative test does not exclude all inherited causes. Contextual genetics links segregation, mechanism and phenotype.

Endomyocardial biopsy is reserved for situations in which the result can change management, such as specific unresolved inflammatory, infiltrative or metabolic diagnoses. It is not necessary to confirm a trabecular morphology or every systemic dysfunction. The specimen may also fail to represent focal disease. The biopsy decision balances expected information, risk and less invasive alternatives.

Mechanism-directed treatment

Therapy has two simultaneous axes: correcting the cause and protecting the heart. Hormonal normalization, documented repletion, control of cirrhosis or renal optimization do not replace treatment of heart failure, arrhythmias and thromboembolism when indicated. Likewise, effective cardiac therapy does not make a reversible cause superfluous. The dual target prevents both passive waiting and purely symptomatic treatment.

Standard heart failure drugs are adapted to blood pressure, volume, kidney function, potassium, dynamic obstruction and acute phase. In Takotsubo with outflow tract obstruction, an appropriate strategy differs from that for shock without obstruction; in cirrhosis, baseline vasodilation limits some treatments; in dialysis, pharmacokinetics and hyperkalemia modify doses and monitoring. Individual physiology takes precedence over an identical protocol for all etiologies.

Anticoagulation and devices are not prescribed solely on the basis of the words noncompaction, Takotsubo or uremia. Atrial fibrillation, thrombus, previous embolism, function, scar and arrhythmic risk determine indications according to the relevant evidence. A transient phenotype also requires distinguishing acute-phase risk from risk after recovery. Proportionate prevention avoids both omission and unnecessary permanent medicalization.

Exercise and rehabilitation are prescribed after defining function, rhythm and systemic disease. Isolated trabeculation does not automatically justify exclusion from sport; advanced cirrhosis, dialysis and malnutrition require programs compatible with frailty and catabolism. After Takotsubo, return to activity considers recovery, triggers, arrhythmias and psychological state. Recovered function should translate into a feasible life, not merely a normal report.

Surveillance, prognosis and communication

Follow-up frequency depends on function, scar, symptoms, rhythm and control of the cause. An adult with incidental hypertrabeculation and a normal evaluation does not require the same pathway as a syndromic child or a patient with LGE and dysfunction. In systemic forms, cardiac assessments are synchronized with phases that change loading conditions, such as TIPS, dialysis, endocrine correction or refeeding. Dynamic surveillance responds to actual risk, not to the most alarming label.

The most robust prognostic determinants remain ventricular dysfunction, dilation, fibrosis, arrhythmias, syncope, thromboembolic events and severity of the causal disease. The amount of isolated trabeculation does not demonstrate independent risk in adults, whereas normalization of ejection fraction after Takotsubo is not equivalent to zero risk. The prognostic marker should be distinguished from the criterion used to name the phenotype.

Communication should make explicit what is certain, what is suspected and which event will change interpretation. Saying morphologic finding rather than disease avoids anxiety when significance is indeterminate; explaining the possible severity of a reversible condition avoids false reassurance. Relatives are also involved only when there is a plausible inherited basis. Precision in communication is part of clinical safety.

These conditions ultimately show why cardiomyopathy cannot be read as a snapshot of the ventricle. Shape, tissue, function, rhythm, the extracardiac system and time must converge in a verifiable causal model. The best outcome is not to assign every patient to a box, but to recognize which component is harmless, which is reversible and which requires permanent protection. Etiologic medicine transforms a residual group into specific clinical pathways.